Gadolinium-Based Contrast Agents Market Report 2026

Gadolinium-Based Contrast Agents Market Overview

• Gadolinium-Based Contrast Agents market size has reached to $1.88 billion in 2025 • Expected to grow to $2.57 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: Rising Number Of Magnetic Resonance Imaging (MRI) Scans Fueling The Growth Of The Market Due To Increasing Demand For Accurate, Non-Invasive Diagnostic Imaging • Market Trend: Advancements In High-Relaxivity Macrocyclic Agents For Enhanced Diagnostic Precision With Reduced Gadolinium Exposure • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gadolinium-Based Contrast Agents Market?

Gadolinium-based contrast agents are specialized medical formulations containing gadolinium ions that are used to improve the clarity and differentiation of tissues during magnetic resonance imaging. Their purpose is to enhance the visibility of abnormalities, blood flow, and organ structures, allowing healthcare professionals to obtain more accurate diagnostic images. The main types of gadolinium-based contrast agents areincluding linear gadolinium-based contrast agents and macrocyclic gadolinium-based contrast agents. Linear gadolinium-based contrast agents refer to MRI contrast media in which gadolinium ions are bound in an open-chain chemical structure, enhancing image clarity by improving the visualization of tissues, blood vessels, and abnormalities during imaging. The magnetic resonance imaging (mri) procedure types are including enhanced magnetic resonance imaging scans, cardiac magnetic resonance imaging, functional MRI, and whole-body screening magnetic resonance imaging. The applications are such as magnetic resonance imaging, magnetic resonance angiography, and others, and the key end users such as hospitals, diagnostic centers, ambulatory surgical centers, and others.

What Is The Gadolinium-Based Contrast Agents Market Growth Forecast?

The gadolinium-based contrast agents market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2030at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to rising patient volume requiring diagnostic imaging, increasing investments in healthcare infrastructure, a growing number of outpatient imaging centers, expanding insurance coverage for magnetic resonance imaging procedures, and increasing emphasis on early disease screening. Major trends in the forecast period include advancements in magnetic resonance imaging contrast chemistry technologies, increasing research and development in safer gadolinium formulations, development of macrocyclic gadolinium-based contrast agents, innovation in low-dose contrast technologies, and advancement in artificial intelligence-supported imaging analysis systems.

What Is The Driver Of The Gadolinium-Based Contrast Agents Market?

The rising number of magnetic resonance imaging (MRI) scans is expected to propel the growth of the gadolinium-based contrast agents market going forward. Magnetic resonance imaging (MRI) scans refer to non-invasive diagnostic procedures that use powerful magnets and radio waves to create detailed images of organs and tissues inside the body. The number of magnetic resonance imaging (MRI) scans is rising due to the expanding geriatric population worldwide, which experiences a higher prevalence of chronic conditions that necessitate detailed, non-invasive soft tissue imaging for accurate diagnosis and treatment planning. Gadolinium-based contrast agents in magnetic resonance imaging support magnetic resonance imaging (MRI) scans by improving the visibility of blood vessels, tumors, and inflamed tissues, enabling more accurate diagnosis and treatment planning. For instance, in December 2024, according to NHS England, a UK-based publicly funded healthcare system, magnetic resonance imaging scans in England increased from 361,705 in August 2023 to 365,270 in August 2024, with a rolling 12-month total from September 2023 to August 2024 reaching 4,504,615 scans. Therefore, the rising number of magnetic resonance imaging scans is driving the growth of the gadolinium-based contrast agents industry.

Key Players In The Global Gadolinium-Based Contrast Agents Market

Major companies operating in the gadolinium-based contrast agents market are Bayer AG, Siemens Healthineers, Medline Imaging Pvt. Ltd., GE HealthCare Technologies Inc., United Imaging Healthcare, J.B. Chemicals & Pharmaceuticals Ltd., iMax Diagnostic Imaging Ltd., Zhejiang Starry Pharmaceutical Co. Ltd., Trivitron Diagnostic Imaging R&D, Canon Medical Systems Corporation, Beijing Beilu Pharmaceutical Co. Ltd., Unijules Life Sciences Ltd., Vision Pharma Pvt. Ltd., Livealth Biopharma Pvt. Ltd., China Resources Zizhu Pharmaceutical Co. Ltd., Kiran Medical Systems Ltd., Unispire Biopharma Pvt. Ltd.

Global Gadolinium-Based Contrast Agents Market Trends and Insights

Major companies operating in the gadolinium-based contrast agents market are focusing on developing advanced product features, such as highly stable macrocyclic agents with elevated relaxivity, to optimize patient safety and diagnostic image quality. Highly stable macrocyclic agents with elevated relaxivity refer to contrast molecules built on ring-shaped chelating structures that tightly bind metal ions and produce stronger magnetic resonance signals, enabling clearer imaging at lower doses with reduced risk of metal release in the body. For instance, in February 2023, Guerbet LLC, a France-based medical imaging company, announced the commercial launch and first patient dosing of Elucirem (gadopiclenol) injection. The solution is the first highly stable macrocyclic gadolinium-based contrast agent (GBCA) with the highest relaxivity in its class, designed to be used at half the conventional gadolinium dose while revealing high-quality images for the detection of lesions in the brain, spine, and associated tissues in adults and children aged 2 years and older. The agent also provides improved contrast between lesions and surrounding tissues through accelerated proton relaxation, offering a significant improvement for neuroradiology practices.

What Are Latest Mergers And Acquisitions In The Gadolinium-Based Contrast Agents Market?

In September 2024, Zydus Lifesciences Ltd., an India-based innovation-driven healthcare company, entered into an exclusive licensing and supply agreement with Viwit Pharmaceuticals Co. Ltd. to commercialize gadolinium-based MRI contrast agents in the US market. Through this agreement, Viwit Pharmaceuticals will be responsible for ANDA submission, manufacturing, and supply of gadobutrol injection (generic GADAVIST) and gadoterate meglumine injection (generic DOTAREM), while Zydus will exclusively market, distribute, and sell the products in the United States following regulatory approval. Viwit Pharmaceuticals Co. Ltd. is a US-based innovation-driven biopharmaceutical and healthcare company.

What Defines the Gadolinium-Based Contrast Agents Market?

The gadolinium-based contrast agents market consists of sales of gadolinium-containing contrast media used to enhance the visibility of internal organs, tissues, and blood vessels during magnetic resonance imaging procedures. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gadolinium-Based Contrast Agents Market Report 2026?

The gadolinium-based contrast agents market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gadolinium-based contrast agents industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.